PT  - JOURNAL ARTICLE
AU  - Sheikh, Abu Baker
AU  - Nguyen, Anthony
AU  - Sheikh, Abdul Ahad Ehsan
AU  - Javed, Nismat
AU  - Leyba, Katarina
AU  - Shekhar, Rahul
TI  - Von Meyenburg Complexes and Malignancy: A Systematic Review
AID  - 10.1101/2021.04.17.21255674
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.17.21255674
4099  - http://medrxiv.org/content/early/2021/04/22/2021.04.17.21255674.short
4100  - http://medrxiv.org/content/early/2021/04/22/2021.04.17.21255674.full
AB  - Von Meyenburg Complexes (VMC) are benign lesions secondary to ductal plate malformations. These are relatively rare in adults and are often asymptomatic, with many lesions being diagnosed on imaging. Despite these benign characteristics, VMC have the potential to undergo malignant changes leading to conditions such as cholangiocarcinoma and other cancers. The objective of the review is to report and analyze the cases of biliary hamartomas which were associated with malignancy. We performed a structured systematic review of literature and identified 31 cases of biliary duct hamartomas associated with malignancy. The mean age at onset was 61 years±13 (min 19 to max 88) with the majority of the patients being male (64.5%). Of all cases, 41.9% reported symptoms (13/31 cases) with the most common symptom being abdominal pain (32.3%). Biopsies reported malignancy in 77.4% of cases (24/31 cases) with the most common reported associated malignancy being cholangiocarcinoma 54.8% (17/31). 93.3% of the cases underwent surgical intervention (28/30 cases). VMC are an important entity with malignancy potential which is under-reported. Presence of ‘red flag’ symptoms such as weight loss and obstructive jaundice in patients with diagnosed biliary hamartomas should prompt an evaluation for malignancy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research received no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the guidelines of the Declaration of Helsinki, and presented fully anonymised non-identifiable information that did not require prior approval by the Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be made available on reasonable request from the corresponding author.